1. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis 
Laurent Peyrin-Biroulet, Silvio Danese, Marjorie Argollo, Lieven Pouillon, Spyros Peppas, Marien Gonzalez-Lorenzo, Theodore Lytras, Stefanos Bonovas 
Clinical Gastroenterology and Hepatology 
Volume 17, Issue 5, Pages e2 (April 2019)
DOI: /j.cgh
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1
Summary of the evidence search and selection process (flow chart).
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

3. Figure 2
Forest plot of incidence rates of loss of response to vedolizumab maintenance therapy in Crohn’s disease. CI, confidence interval.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

4. Figure 3
Forest plot of incidence rates of loss of response to vedolizumab maintenance therapy in ulcerative colitis. CI, confidence interval.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

5. Figure 4
Forest plot of efficacy of vedolizumab intensification in secondary nonresponders with inflammatory bowel disease. CI, confidence interval.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions